XENOTHERA and its partner Excelya announce the recruitment of the first patient in the EUROXAV clinical trial of its COVID XAV-19 treatment
# COVID19 # Clinical trial #Treatment #Polyclonal antibiotics
The biotechnology company XENOTHERA has started the European clinical trial of its anti-COVID treatment, XAV-19. The Nantes laboratory is the sponsor of the trial, called EUROXAV, which will be carried out by Excelya, a leading European contract research organization (CRO) specializing in clinical research. EUROXAV is a multicenter, double-blind phase III trial that will recruit 722 patients with moderate COVID, hospitalized or monitored remotely. The trial will take place in Greece, Bulgaria, Romania, Spain and Turkey.
The first patient in the trial was recruited on April 28e at the center of Professor Poulakou (GR04) in Greece. The cohort of 722 patients will complete the 398 patients of the POLYCOR trial, a trial carried out in 35 French hospitals under the sponsorship of the Nantes University Hospital, which has just completed its recruitment phase with results expected in the summer of 2021.
“Excelya is very proud to support XENOTHERA in the development of XAV19, which shows great promise in the battle against COVID19. After having taken several months to develop the EUROXAV project, the inclusion of this first patient represents an important step. We hope to work quickly. to make the results available and initiate the next steps for the benefit of patients and caregivers, “ mentionned Alan Morgan, CEO of Excelya.
“This step marks the start of the EUROXAV trial, the results of which are awaited with great interest. The objective of the trial is to evaluate the efficacy of XAV-19 in hospitalized and ambulatory patients, which will allow us to analyze the medical value of XAV-19 in clinical situations where there is currently no no satisfactory therapeutic solution. “ comments Odile Duvaux, co-founder and president of XENOTHERA.
XENOTHERA’s drug candidate XAV-19 is a protective polyclonal anti-SARS-CoV-2 antibody similar to the natural human response. Based on a unique and patented proprietary technology, it works through several mechanisms of action, including neutralizing the virus, reducing inflammation and limiting the risk of cytokine storms.
Founded in 2014, XENOTHERA is a Nantes biotechnology company that develops “glyco-humanized” polyclonal antibodies. Its technological platform is based on dual expertise in genetics and immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant in transplantation, has been present in the clinic since 2019. XENOTHERA has also been developing its treatment for coronavirus infections for several years. XAV-19 is the treatment of XENOTHERA for patients at the beginning of hospitalization, it is based on a unique patented antibody production technology, developed and proven for several years by biotechnology.
XENOTHERA, member of the Atlanpole Biotherapies competitiveness cluster, is part of the scientific and medical environment of Pays de la Loire. The company has been supported since its creation by private investors, by the Pays de la Loire region and by BPI France. Since its creation, the company has raised more than 23 million euros to finance all of its products.
For more information: www.xenothera.com
Follow XENOTHERA on social networks: LinkedIn Twitter
About the Excelya group:
Excelya is an independent European contract research organization with more than 800 employees, 17 offices and 12 legal entities spread across Europe. Excelya offers all models of cooperation, from advice to functional service, including full-service. It provides these research services in several sectors, including pharmaceuticals, biotechnology, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials for post-market studies, security, biometrics and market access projects. Excelya is committed to providing leading experts who work hand-in-hand with our customers to accelerate end-to-end drug development, leverage data science and reinvent patient care.
For more information, please visit excelya.com.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20210503005365/en/
Excelya Media Relations:
+33 (6) 47 87 31 41